Evidence map›Paper›PMID 38773655›Full record

ArticleClinical epigenetics2024

Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length.

Olivia Carlund, Elina Thörn, Pia Osterman, Maja Fors, Andy Dernstedt, Mattias N E Forsell, Martin Erlanson, Mattias Landfors, Sofie Degerman, Magnus Hultdin

Abstract read
In one paragraph

Article in Clinical epigenetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Analysis by TeloViewCancers · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Olivia CarlundDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Elina ThörnDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Pia OstermanDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Maja ForsDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Andy DernstedtDepartment of Clinical Microbiology, Infection and Immunology, Umeå University, Umeå, Sweden.
Mattias N E ForsellDepartment of Clinical Microbiology, Infection and Immunology, Umeå University, Umeå, Sweden.
Martin ErlansonDepartment of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden.
Mattias LandforsDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Sofie DegermanDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
Magnus HultdinDepartment of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden. magnus.hultdin@umu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLarge B-cell lymphoma (LBCL) is the most common lymphoma and is known to be a biologically heterogeneous disease regarding genetic, phenotypic, and clinical features. Although the prognosis is good, one-third has a primary refractory or relapsing disease which underscores the importance of developing predictive biological markers capable of identifying high- and low-risk patients. DNA methylation (DNAm) and telomere maintenance alterations are hallmarks of cancer and aging. Both these alterations may contribute to the heterogeneity of the disease, and potentially influence the prognosis of LBCL.

resultsWe studied the DNAm profiles (Infinium MethylationEPIC BeadChip) and relative telomere lengths (RTL) with qPCR of 93 LBCL cases: Diffuse large B-cell lymphoma not otherwise specified (DLBCL, n = 66), High-grade B-cell lymphoma (n = 7), Primary CNS lymphoma (n = 8), and transformation of indolent B-cell lymphoma (n = 12). There was a substantial methylation heterogeneity in DLBCL and other LBCL entities compared to normal cells and other B-cell neoplasms. LBCL cases had a particularly aberrant semimethylated pattern (0.15 ≤ β ≤ 0.8) with large intertumor variation and overall low hypermethylation (β > 0.8). DNAm patterns could not be used to distinguish between germinal center B-cell-like (GC) and non-GC DLBCL cases. In cases treated with R-CHOP-like regimens, a high percentage of global hypomethylation (β < 0.15) was in multivariable analysis associated with worse disease-specific survival (DSS) (HR 6.920, 95% CI 1.499-31.943) and progression-free survival (PFS) (HR 4.923, 95% CI 1.286-18.849) in DLBCL and with worse DSS (HR 5.147, 95% CI 1.239-21.388) in LBCL. These cases with a high percentage of global hypomethylation also had a higher degree of CpG island methylation, including islands in promoter-associated regions, than the cases with less hypomethylation. Additionally, telomere length was heterogenous in LBCL, with a subset of the DLBCL-GC cases accounting for the longest RTL. Short RTL was independently associated with worse DSS (HR 6.011, 95% CI 1.319-27.397) and PFS (HR 4.689, 95% CI 1.102-19.963) in LBCL treated with R-CHOP-like regimens.

conclusionWe hypothesize that subclones with high global hypomethylation and hypermethylated CpG islands could have advantages in tumor progression, e.g. by inactivating tumor suppressor genes or promoting treatment resistance. Our findings suggest that cases with high global hypomethylation and thus poor prognosis could be candidates for alternative treatment regimens including hypomethylating drugs.

Indexed as

DNA MethylationLymphoma, Large B-Cell, DiffuseAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCpG IslandsCyclophosphamideDoxorubicinEpigenesis, GeneticFemaleHumansMaleMiddle AgedPrednisonePrognosisCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineDiffuse large-B cell lymphomaDNA methylationHigh-grade B-cell lymphomaPredictive markersPrimary CNS lymphomasSurvivalTelomere length

Identifiers

PMID38773655
PMCPMC11110316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.